Journal Article

DZNE-2020-02926

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Adult-onset fluoxetine treatment does not improve behavioral impairments and may have adverse effects on the Ts65Dn mouse model of Down syndrome.

Heinen, M. (First author)DZNE* ; Hettich, M. M.DZNE* ; Ryan, D. P.DZNE* ; Schnell, S.DZNE* ; Paesler, K.DZNE* ; Ehninger, D. (Last author)DZNE*

2012
Hindawi New York, NY

This record in other databases:    

Please use a persistent id in citations: doi:10.1155/2012/467251

Abstract: Down syndrome is caused by triplication of chromosome 21 and is associated with neurocognitive phenotypes ranging from severe intellectual disability to various patterns of more selective neuropsychological deficits, including memory impairments. In the Ts65Dn mouse model of Down syndrome, excessive GABAergic neurotransmission results in local over-inhibition of hippocampal circuits, which dampens hippocampal synaptic plasticity and contributes to cognitive impairments. Treatments with several GABA(A) receptor antagonists result in increased plasticity and improved memory deficits in Ts65Dn mice. These GABA(A) receptor antagonists are, however, not suitable for clinical applications. The selective serotonin reuptake inhibitor fluoxetine, in contrast, is a widely prescribed antidepressant that can also enhance plasticity in the adult rodent brain by lowering GABAergic inhibition. For these reasons, we wondered if an adult-onset 4-week oral fluoxetine treatment restores spatial learning and memory impairments in Ts65Dn mice. Fluoxetine did not measurably improve behavioral impairments of Ts65Dn mice. On the contrary, we observed seizures and mortality in fluoxetine-treated Ts65Dn mice, raising the possibility of a drug × genotype interaction with respect to these adverse treatment outcomes. Future studies should re-address this in larger animal cohorts and determine if fluoxetine treatment is associated with adverse treatment effects in individuals with Down syndrome.

Keyword(s): Selective Serotonin Reuptake Inhibitors: adverse effects (MeSH) ; Animals (MeSH) ; Behavior, Animal: drug effects (MeSH) ; Body Weight: drug effects (MeSH) ; Cell Count (MeSH) ; Cognition Disorders: drug therapy (MeSH) ; Cognition Disorders: psychology (MeSH) ; Down Syndrome: drug therapy (MeSH) ; Down Syndrome: genetics (MeSH) ; Down Syndrome: psychology (MeSH) ; Female (MeSH) ; Fluoxetine: adverse effects (MeSH) ; Fluoxetine: pharmacology (MeSH) ; GABA-A Receptor Antagonists: pharmacology (MeSH) ; Genotype (MeSH) ; Image Processing, Computer-Assisted (MeSH) ; Immunohistochemistry (MeSH) ; Male (MeSH) ; Maze Learning: drug effects (MeSH) ; Memory Disorders: drug therapy (MeSH) ; Memory Disorders: etiology (MeSH) ; Mice (MeSH) ; Mice, Inbred C3H (MeSH) ; Mice, Inbred C57BL (MeSH) ; Motor Activity: drug effects (MeSH) ; Seizures: chemically induced (MeSH) ; Seizures: mortality (MeSH) ; Serotonin Uptake Inhibitors: adverse effects (MeSH) ; Serotonin Uptake Inhibitors: pharmacology (MeSH) ; Selective Serotonin Reuptake Inhibitors: pharmacology (MeSH) ; GABA-A Receptor Antagonists ; Serotonin Uptake Inhibitors ; Fluoxetine

---

Contributing Institute(s):

1. Translational Biogerontology (AG Ehninger)
2. Animal Facility Bonn (Animal Facility Bonn)
3. Cell and Animal Models of Neurodegeneration (AG Mandelkow 2)

Research Program(s):

1. 342 - Disease Mechanisms and Model Systems (POF3-342) (POF3-342)

Appears in the scientific report 2012

---

Database coverage:
; ; ; ; BIOSIS Previews ; Clarivate Analytics Master Journal List ; DOAJ Seal ; Ebsco Academic Search ; NCBI Molecular Biology Database ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---